Treats molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). Sold as Dojolvi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Triheptanoin (sold as Dojolvi), first approved Jun 30, 2020, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Dojolvi | Part D | $3.4M | +17% | 23 |
| Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyPyruvate Dehydrogenase Complex Deficiency · Jirair Krikor Bedoyan | Phase 1 | Recruiting | Apr 1, 2024 |
| A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODLong-chain Fatty Acid Oxidation Disorders (LC-FAOD) · Ultragenyx Pharmaceutical Inc | Phase 3 | Active, not recruiting | Jul 6, 2023 |
| Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring ProgramLong-chain Fatty Acid Oxidation Disorders (LC-FAOD) · Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | Nov 17, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 30, 2020 | DojolviNDA 213687 · New molecular entity | Ultragenyx Pharm Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
